文献速递慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病颅内动脉瘤筛查具有成本效益

Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective.
PubMed 文献 · Kidney Int · 2017-10-20

该单中心队列纳入495例连续ADPKD患者,评估靶向颅内动脉瘤筛查的效果与成本效益。中位随访5.9年,5例非致死性动脉瘤破裂,发病率2.0(0.87-4.6)/1000患者年;破裂多发生于无家族风险者。成本效用分析提示系统性筛查较靶向筛查具有成本效益,可增益0.68质量调整生命年。

要点

  • ADPKD患者颅内动脉瘤破裂率较高,且多发生于无家族风险因素者。
  • 系统性筛查较靶向筛查具有成本效益,可增益0.68 QALY。
  • 建议可对所有ADPKD患者提供颅内动脉瘤筛查。

核心结论

  • 尽管实施靶向筛查,ADPKD患者颅内动脉瘤破裂率仍较高,且主要涉及无家族风险因素的患者。
  • 成本效用分析提示,颅内动脉瘤筛查可考虑提供给所有ADPKD患者。

研究设计与样本

  • 单中心队列研究,纳入495例连续ADPKD患者,接受靶向颅内动脉瘤筛查。
  • 110例有颅内动脉瘤家族史者被建议行脑磁共振血管造影(组1),385例无家族风险者未打算建议筛查(组2)。
  • 回顾性分析磁共振血管造影结果、预防性修复、破裂事件及筛查策略的成本效益。

主要发现

  • 中位随访5.9年,发生5例非致死性颅内动脉瘤破裂,发病率2.0(0.87-4.6)/1000患者年。
  • 组1中90%患者接受筛查,检出颅内动脉瘤14例,5例预防性治疗,1例尽管监测仍破裂。
  • 组2中21%患者接受筛查,检出颅内动脉瘤5例,1例预防性治疗;组2发生4例破裂。

关键数值与推荐

  • 系统性筛查被认为具有成本效益,较靶向筛查增益0.68质量调整生命年。

临床怎么用

  • 临床可考虑对所有ADPKD患者提供颅内动脉瘤筛查,而不仅限于有家族风险者。

局限性

  • 单中心回顾性队列设计。
  • 组2中仅21%患者实际接受筛查,非随机分组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intracranial aneurysm rupture is a dramatic complication of autosomal dominant polycystic kidney disease (ADPKD). It remains uncertain whether screening should be widespread or only target patients with risk factors (personal or familial history of intracranial aneurysm), with an at-risk profession, or those who request screening. We evaluated this in a single-center cohort of 495 consecutive patients with ADPKD submitted to targeted intracranial aneurysm screening. Cerebral magnetic resonance angiography was proposed to 110 patients with a familial history of intracranial aneurysm (group 1), whereas it was not our intention to propose it to 385 patients without familial risk (group 2). Magnetic resonance angiography results, intracranial aneurysm prophylactic repair, rupture events, and cost-effectiveness of intracranial aneurysm screening strategies were retrospectively analyzed. During a median follow up of 5.9 years, five non-fatal intracranial aneurysm ruptures occurred (incidence rate 2.0 (0.87-4.6)/1000 patients-year). In group 1, 90% of patients were screened and an intracranial aneurysm was detected in 14, treated preventively in five, and ruptured in one patient despite surveillance. In group 2, 21% of patients were screened and an intracranial aneurysm was detected in five, and treated preventively in one. Intracranial aneurysm rupture occurred in four patients in group 2. Systematic screening was deemed cost-effective and provides a gain of 0.68 quality-adjusted life years compared to targeted screening. Thus, the intracranial aneurysm rupture rate is high in ADPKD despite targeted screening, and involves mostly patients without familial risk factors. Hence, cost-utility analysis suggests that intracranial aneurysm screening could be proposed to all ADPKD patients.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Flahault A, Trystram D, Nataf F, et al. Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective. Kidney Int. 2017. PMID: 29061331. doi:10.1016/j.kint.2017.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。